Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nicotinamide N-methyltransferase antisense oligonucleotide
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
A nicotinamide N-methyltransferase antisense oligonucleotide is a therapeutic agent designed to inhibit the enzyme nicotinamide N-methyltransferase (NNMT). NNMT plays a crucial role in metabolism by methylating nicotinamide, a precursor to NAD+. Inhibition of NNMT leads to increased levels of S-adenosylmethionine (SAM) and NAD+ in adipose tissue, and upregulates the activity and expression of ornithine decarboxylase (ODC) and spermidine-spermine N(1)-acetyltransferase (SSAT). This results in increased polyamine flux and enhanced oxygen consumption in adipocytes. Furthermore, NNMT inhibition influences histone H3 lysine 4 methylation. This mechanism suggests its potential as a treatment for obesity and type 2 diabetes by augmenting cellular energy expenditure.
- Other names
- NNMT antisense oligonucleotideantisense oligonucleotide targeting nicotinamide N-methyltransferase
02
Targets
NNMT (Nicotinamide N-methyltransferase)
Beyond the preview
Go deeper on nicotinamide N-methyltransferase antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nicotinamide N-methyltransferase antisense oligonucleotide.